|Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?|
ARRY-614 was found to inhibit inflammation and cytokine-dependent tumor growth in preclinical models. MDS are diseases characterized by over-production of myelosuppressive cytokines leading to aberrant apoptosis in hematologic progenitor cells and ...
Seeking Alpha - Sun, 12 May 2013 15:31
|Pfizer halts study of lymphoma drug unlikely to help survival|
“Hematologic cancers are a complex group of diseases, with more than 70 different types of lymphomas, leukemias or myelomas that require unique treatment options,” Mace Rothenberg, Pfizer's senior vice president of clinical development and medical ...
Times LIVE - Tue, 21 May 2013 00:24
|Pfizer Stops Lymphoma Drug Late-Stage Trial Due To Ineffectiveness|
RTT News - Mon, 20 May 2013 14:51
|Pfizer discontinues Phase 3 non-hodgkin lymphoma study of inotuzumab ...|
Pharmaceutical Business Review - Mon, 20 May 2013 22:39
|NIH Funds Studies to Improve Type 2 and Prediabetes Treatment|
The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases. Spanning the full spectrum of medicine ...
eNews Park Forest - Thu, 23 May 2013 09:08
|Acceleron's ACE-536 Preclinical Data Presentation Selected for Best Abstract ...|
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, today announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito ...
The Herald | HeraldOnline.com - Fri, 10 May 2013 05:39
|Johnson & Johnson to Submit 10 New Product Filings by 2017|
Among the late-stage products for which it plans to file for regulatory approval are simeprevir for hepatitis C, ibrutinib and daratumumab for the treatment of hematologic malignancies, and sirukumab and guselkumab for important immune mediated diseases.
Wall Street Journal - Thu, 23 May 2013 05:25
|Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector ...|
The Pharma Letter - Fri, 24 May 2013 01:25
|J&J taps top blockbusters in the pipeline, lays out global R&D strategy|
FierceBiotech - Thu, 23 May 2013 05:44
|ONS: Infection Risk, Prevention, and Management|
Laura Zitella: Well, patients with hematologic malignancies have the greatest risk of infection, in general, and for each specific hematologic disease, there are specific recommendations. So, in the book, we included that for each disease group. So ...
Cancer Network - Mon, 29 Apr 2013 10:45
|Sjogren's Carries Heavy Disease Burden|
One patient had four additional autoimmune conditions along with primary Sjögren's, Abrol said. Hematologic abnormalities included hypergammaglobulinemia in 36.8% and monoclonal gammopathy in just under 10%. Nervous system involvement and ...
MedPage Today - Fri, 26 Apr 2013 15:46
|Dr. Mary Horowitz Inducted into Association of American Physicians|
Mary Horowitz, MD, MS, Robert A. Uihlein, Jr. Chair in Hematologic Research, professor of medicine and chief of the division of hematology and oncology at the Medical College of Wisconsin (MCW), was inducted into the Association of American ... Dr ...
Wauwatosa Now - Wed, 22 May 2013 12:59